ClinicalTrials.gg
RecruitingNCT07218523CLARITYUpdated Oct 7, 2026

A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy

A Phase 3 interventional study of PLENVU® and Sodium picosulfate in Bowel Cleansing Prior to Clinical Procedures, sponsored by Norgine. Recruiting at 46 sites in 10 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Norgine · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Oct 7, 2026First sites in Croatia and PortugalSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Study summary

The purpose of the study is to assess the efficacy, safety and tolerability of PLENVU® by measuring its bowel cleansing success rate compared to sodium picosulfate in paediatric participants aged less than 18 years who are scheduled to undergo a colonoscopy. Colonoscopy is a crucial procedure that helps to diagnose and manage various gastrointestinal (GI) conditions in paediatric patients. An adequate level of bowel preparation and cleansing is essential for effective colonoscopy to allow proper visualisation of the bowel.

Read the detailed description

This is a multicentre, active-controlled study in which the participants will be randomised 1:1 into one of two treatment groups - PLENVU® or sodium picosulfate in a 2-day split dosing regimen. The study will include -

  1. A Screening Period of up to 28 days (Day -28 to Day -1).
  2. A Treatment Period (Day 1 to Day 2) - Participants will be randomised to receive either PLENVU® or sodium picosulfate. Participants will be admitted into the Clinical Research Unit (CRU) on Day 1 and will remain in the CRU for the duration of study intervention administration (Day 1 and Day 2) and colonoscopy (Day 2). Participants will be discharged on Day 2 following the colonoscopy and evaluation of colon cleansing.
  3. A safety follow-up call or CRU visit (Day 9 ± 2 days).
02

Conditions studied

  • Bowel Cleansing Prior to Clinical Procedures

Keywords

  • Colonoscopy
  • Paediatric
  • Harefield Cleansing Scale
  • Boston Bowel Preparation Scale
  • Plenvu
  • Polyethylene Glycol (PEG)
  • Bowel Cleansing
03

In context

Lead sponsor

Norgine is the lead sponsor of 54 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who require a colonoscopy.
  • Must weigh a minimum of 10 kg, and participants aged 1 to \< 4 years of age must be above the 10th percentile of weight for age.
  • Must have a negative urine pregnancy test (or serum if a urine pregnancy test cannot be confirmed as negative [e.g. three ambiguous results]) within 24 hours before the first dose of study intervention.
  • Must use a highly effective method of (failure rate \< 1% per year) from Day 1 and throughout the Safety Follow-up Period.
  • Must not be breastfeeding.
  • Participant is able to receive regular external feeding without breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Has a past history within last 12 months or current episode of severe constipation (requiring repeated use of laxatives/enema or physical intervention before resolution).
  • Has known or suspected ileus, GI obstruction, gastric retention, bowel perforation, toxic colitis, ischaemic colitis, or megacolon.
  • Has ongoing severe acute inflammatory bowel disease that contraindicates colonoscopy.
  • Participant has history of significant GI surgeries.
  • Has known glucose-6-phosphate dehydrogenase (G6PD) deficiency or phenylketonuria.
  • Participant has a past history within the last 12 months or evidence of any ongoing (ECG) abnormalities (e.g. arrhythmias).
  • Has a history of uncontrolled hypertension.
  • Participant has regularly used laxatives or colon motility altering drugs in the last month (i.e. more than two times per week) and/or has used one or more laxatives within 72 hours prior to administration of the preparation.
  • Has known or allergic reaction to PEG, ascorbic acid, sodium picosulfate, magnesium oxide, or any other component of the product or comparator.
  • Received or scheduled to receive any vaccines or devices within one week prior to first dose of study intervention.
  • Has a significant neurological disorder or a past history of seizures (excluding simple febrile seizures) or is currently on medication lowering seizure threshold (e.g. tricyclic antidepressants) or has used seizure threshold lowering medication within 14 days prior to administration of the preparation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    PLENVU®

    Participants will receive PLENVU® in a 2-day split dosing regimen.

    Drug: PLENVU®

  • Active comparator
    Sodium picosulfate

    Participants will receive sodium picosulfate in a 2-day split dosing regimen according to the local label.

    Drug: Sodium picosulfate

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving adequate bowel cleansing based on Boston Bowel Preparation Scale (BBPS)

    To describe the success rate of bowel cleansing in paediatric participants after administration of PLENVU® or sodium picosulfate as measured by the BBPS. The BBPS is a scoring system used to assess bowel cleanliness during colonoscopy. The scale ranges from 0 to 3, evaluating the three colonic segments (i.e. right colon, transverse colon, and left colon) where a score of 0 indicates an unprepared colon segment with mucosa not visible due to solid stool, and 3 indicates mucosa of colon segment seen well, with bowel cleansing success defined as a score of ≥2 in all three segments.

    Time frame: Day 2

Secondary outcomes

  1. Percentage of participants achieving successful bowel cleansing based on Harefield Cleansing Scale (HCS)

    To describe the success rate of bowel cleansing in paediatric participants after administration of PLENVU® or sodium picosulfate as measured by the HCS. The HCS is scoring system used to assess bowel cleanliness during colonoscopy. The scale ranges from 0 to 4 evaluating five segments (i.e. ascending colon, transverse colon, descending colon, sigmoid colon and rectum). The scores of the five segments will be the basis for a final grading of A, B, C, or D. Success is defined as a HCS grade of A or B.

    Time frame: Day 2

  2. Number of participants with Adverse events (AEs) and Serious adverse events (SAEs)

    To determine the safety of PLENVU® as compared to sodium picosulfate in paediatric participants.

    Time frame: From Screening (Day -28 to Day -1) to safety follow-up (Day 9 ± 2 days)

  3. Number of participants with a response on the Likert Scale

    To determine the tolerability, palatability and acceptability of PLENVU® as compared to sodium picosulfate. A paediatric 5-point Likert Scale will be used to assess the tolerability, palatability and acceptability. It uses a combination of facial expressions and simple language to make it easier for children to understand and respond.

    Time frame: Day 1 and Day 2

07

Study locations

41 of 46 sites recruiting
  • Universitair Ziekenhuis Antwerpen (UZA)
    Edegem, Antwerp 2650, Belgium
    Recruiting
  • Universitair Ziekenhuis Brussel (AZ-VUB - Academisch Ziekenhuis der Vrije Universiteit Brussel)
    Jette, Brussels Capital 1090, Belgium
    Recruiting
  • Clinique CHC MontLegia
    Alleur, Liege 4000, Belgium
    Recruiting
  • Clinical Hospital Centre Rijeka
    Rijeka, Primorje-Gorski Kotar County 51000, Croatia
    Recruiting
  • Krankenhaus Barmherzige Brueder Regensburg - Klinik fuer Kinder- und Jugendmedizin
    Regensburg, Bavaria 93049, Germany
    Recruiting
  • Universitaetsklinikum Muenster (UKM) - Klinik fuer Kinder- und Jugendmedizin - Allgemeine Paediatrie
    Münster, North Rhine-Westphalia 48149, Germany
    Recruiting
  • Helios Uniklinikum Wuppertal
    Wuppertal, North Rhine-Westphalia 42283, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Universitätsmedizin Der Johannes Gutenberg-Universität Mainz KöR
    Mainz, Rhineland-Palatinate 55131, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Charité Universitätsmedizin Berlin
    Berlin, State of Berlin 049006, Germany
    Recruiting
  • Semmelweis Egyetem Gyermekgyogyaszati Klinika Bokay Utcai Reszleg
    Budapest, Budapest 1083, Hungary
    Recruiting
  • Heim Pal Orszagos Gyermekgyogyaszati Intezet
    Budapest, Budapest 1089, Hungary
    Recruiting
  • Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktato Korhaz
    Miskolc, Miskolc 3526, Hungary
    Recruiting
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
    Bergamo, Bergamo 24127, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Meyer IRCCS
    Florence, Firenze 50139, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Gaetano Martino
    Messina, Messina 98124, Italy
    Recruiting
  • Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda
    Milan, Milano 20122, Italy
    Recruiting
  • Azienda Ospedaliera di Rilievo Nazionale (AORN) Santobono Pausilipon
    Naples, Napoli 80129, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Federico II - Pediatria Generale
    Naples, Napoli 80131, Italy
    Recruiting
  • AOU Università degli studi della Campania Luigi Vanvitelli, Policlinico di Napoli - Pediatria
    Naples, Napoli 80138, Italy
    Recruiting
  • Azienda Ospealiero Universitaria Policlinico Umberto I
    Roma, Roma 00161, Italy
    Recruiting
  • Policlinico Gemelli - Endoscopia Digestiva Chirurgica
    Roma, Roma 00168, Italy
    Recruiting
  • Azienda Ospedaliero-Universitaria Sant'Andrea - Pediatria
    Roma, Roma 00189, Italy
    Withdrawn

    Not enrolling at this site — choose another above.

  • Amphia Hospital - Pediatrics
    Breda, North Brabant 4818 CK, Netherlands
    Recruiting
  • Amsterdam UMC - Pediatrics
    Amsterdam, North Holland 1105 AZ, Netherlands
    Recruiting
  • Isala Klinieken
    Zwolle, Overijssel 8025 AB, Netherlands
    Recruiting
  • Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu - Oddzial Pediatrii i Gastroenterologii
    Torun, Kuyavian-Pomeranian Voivodeship 87-100, Poland
    Recruiting
  • Uniwersytecki Szpital Dzieciecy w Krakowie
    Krakow, Lesser Poland Voivodeship 30-663, Poland
    Recruiting
  • Instytut "Pomnik - Centrum Zdrowia Dziecka" - Oddzial Gastroenterologii, Hepatologii, Zaburzen Odzywiania i Pediatrii
    Warsaw, Masovian Voivodeship 04-730, Poland
    Recruiting
  • Uniwersytecki Dzieciecy Szpital Kliniczny Imienia Ludwika Zamenhofa w Bialymstoku - Klinika Pediatrii, Gastroenterologii, Hepato
    Bialystok, Podlaskie Voivodeship 15-274, Poland
    Recruiting
  • Gdanski Uniwersytet Medyczny (GUMed) - Katedra i Klinika Pediatrii, Gastroenterologii, Alergologii i Zywienia Dzieci
    Gdansk, Pomeranian Voivodeship 80-803, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Samodzielny Publiczny Szpital Kliniczny Nr 1 im. prof. Stanislawa Szyszko SUM w Katowicach Oddzial Gastroenterologii i Hepatolog
    Zabrze, Silesian Voivodeship 41-800, Poland
    Recruiting
  • Centro Clínico Académico(CCA) - Braga, Associação (2CA-Braga)
    Braga, Braga District 4710-243, Portugal
    Recruiting
  • Hospital Pediatrico da Unidad Local de Saude de Coimbra
    Coimbra, Coimbra District 3000-602, Portugal
    Not yet recruiting
  • Hospital da Luz S.A.
    Lisbon, Lisbon District 1500-650, Portugal
    Recruiting
  • Unidade Local De Saude De Santo Antonio E.P.E.
    Porto, Porto District 4050-011, Portugal
    Recruiting
  • Complejo Hospitalario Universitario de Ferrol
    Ferrol, A Coruña 15405, Spain
    Recruiting
  • Hospital Universitario Son Espases
    Palma de Mallorca, Balearic Islands 07120, Spain
    Recruiting
  • Parc Tauli Hospital Universitarli
    Sabadell, Barcelona 08208, Spain
    Recruiting
  • Hospital Infantil Universitario Niño Jesús
    Madrid, Madrid 28009, Spain
    Recruiting
  • Hospital Materno Infantil de Málaga
    Málaga, Málaga 29011, Spain
    Recruiting
  • NHS Lothian - Royal Hospital for Children & Young People
    Edinburgh, Edinburgh, City of EH16 4TJ, United Kingdom
    Recruiting
  • Great North Children's Hospital - Royal Victoria Infirmary
    Newcastle upon Tyne, Newcastle Upon Tyne NE1 4LP, United Kingdom
    Recruiting
  • Sheffield Children's NHS Foundation Trust - Sheffield Children's Hospital
    Sheffield, Sheffield S10 2TH, United Kingdom
    Recruiting
  • King's College Hospital NHS Foundation Trust
    London, York SE5 9RS, United Kingdom
    Recruiting
  • Birmingham Women's and Children's NHS Foundation Trust - Birmingham Children's Hospital
    Birmingham, B4 6NH, United Kingdom
    Recruiting
  • Barts Health NHS Trust
    London, E1 1FR, United Kingdom
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2025
First posted
Oct 20, 2025
StartActual
Dec 29, 2025
Primary completionEst.
Jan 6, 2027
CompletionEst.
Jan 6, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added — first sites in Croatia and Portugal. 8 sites changed recruiting status (5 now recruiting, 3 now withdrawn)
Show 8 sites
  • Helios Uniklinikum Wuppertal · Wuppertal, GermanyRecruiting→Withdrawn
  • Universitätsmedizin Der Johannes Gutenberg-Universität Mainz KöR · Mainz, GermanyRecruiting→Withdrawn
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII · Bergamo, ItalyNot yet recruiting→Recruiting
  • Azienda Ospedaliera di Rilievo Nazionale (AORN) Santobono Pausilipon · Naples, ItalyNot yet recruiting→Recruiting
  • AOU Università degli studi della Campania Luigi Vanvitelli, Policlinico di Napoli - Pediatria · Naples, ItalyNot yet recruiting→Recruiting
  • Uniwersytecki Szpital Dzieciecy w Krakowie · Krakow, PolandNot yet recruiting→Recruiting
  • Uniwersytecki Dzieciecy Szpital Kliniczny Imienia Ludwika Zamenhofa w Bialymstoku - Klinika Pediatrii, Gastroenterologii, Hepato · Bialystok, PolandNot yet recruiting→Recruiting
  • Gdanski Uniwersytet Medyczny (GUMed) - Katedra i Klinika Pediatrii, Gastroenterologii, Alergologii i Zywienia Dzieci · Gdansk, PolandRecruiting→Withdrawn
Show 5 added (4 Portugal, 1 Croatia)
  • Clinical Hospital Centre Rijeka · Rijeka, Croatia
  • Centro Clínico Académico(CCA) - Braga, Associação (2CA-Braga) · Braga, Portugal
  • Hospital Pediatrico da Unidad Local de Saude de Coimbra · Coimbra, Portugal
  • Hospital da Luz S.A. · Lisbon, Portugal
  • Unidade Local De Saude De Santo Antonio E.P.E. · Porto, Portugal
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    5 sites added — first sites in Croatia and Portugal. 8 sites changed recruiting status (5 now recruiting, 3 now withdrawn)
    Show 8 sites
    • Helios Uniklinikum Wuppertal · Wuppertal, GermanyRecruiting→Withdrawn
    • Universitätsmedizin Der Johannes Gutenberg-Universität Mainz KöR · Mainz, GermanyRecruiting→Withdrawn
    • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII · Bergamo, ItalyNot yet recruiting→Recruiting
    • Azienda Ospedaliera di Rilievo Nazionale (AORN) Santobono Pausilipon · Naples, ItalyNot yet recruiting→Recruiting
    • AOU Università degli studi della Campania Luigi Vanvitelli, Policlinico di Napoli - Pediatria · Naples, ItalyNot yet recruiting→Recruiting
    • Uniwersytecki Szpital Dzieciecy w Krakowie · Krakow, PolandNot yet recruiting→Recruiting
    • Uniwersytecki Dzieciecy Szpital Kliniczny Imienia Ludwika Zamenhofa w Bialymstoku - Klinika Pediatrii, Gastroenterologii, Hepato · Bialystok, PolandNot yet recruiting→Recruiting
    • Gdanski Uniwersytet Medyczny (GUMed) - Katedra i Klinika Pediatrii, Gastroenterologii, Alergologii i Zywienia Dzieci · Gdansk, PolandRecruiting→Withdrawn
    Show 5 added (4 Portugal, 1 Croatia)
    • Clinical Hospital Centre Rijeka · Rijeka, Croatia
    • Centro Clínico Académico(CCA) - Braga, Associação (2CA-Braga) · Braga, Portugal
    • Hospital Pediatrico da Unidad Local de Saude de Coimbra · Coimbra, Portugal
    • Hospital da Luz S.A. · Lisbon, Portugal
    • Unidade Local De Saude De Santo Antonio E.P.E. · Porto, Portugal
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07218523
Lead sponsor
Norgine
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 20, 2025
Start date
Dec 29, 2025
Primary completion
Jan 6, 2027 (estimated)
Completion
Jan 6, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Annabel Rigg
Contact
ARigg@norgine.com
+441895453624

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Polyethylene glycol 3350 · Ascorbic Acid · Sodium sulfate · Sodium Chloride · Potassium Chloride

Start the discussion